Ono Pharmaceutical Company, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ono Pharmaceutical Company, Ltd.
Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.
Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.
Among the strong performers, Hanmi benefitted from growth for in-house-developed metabolic disease drugs and China cold syrup sales and Daewoong was boosted by exports of botulinum toxin, while Boryung reported record quarterly sales helped by its flagship antihypertensive.
Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.
- Generic Drugs
- Other Names / Subsidiaries
- Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
- Ono Pharmaceutical Co., Ltd.
- Ono Pharma Taiwan Co., Ltd.